Industry News

• FDA announces new boxed warning on Plavix  The U.S. Food and Drug Administration added a boxed warning to the anti-blood clotting drug Plavix (clopidogrel), alerting patients and health care professionals that the drug can be less effective in people who cannot metabolize the drug to convert it to its active form.
  FDA March 12, 2010  
• Sanofi-aventis and BMS announce important updates to PLAVIX U.S. prescribing info  Sanofi-aventis U.S. and Bristol-Myers Squibb announced revisions to the U.S. prescribing information for PLAVIX(R) (clopidogrel bisulfate), which include a boxed warning.
  Bristol-Myers Squibb Company March 12, 2010  
• Medtronic starts international study of CoreValve(R) Transcatheter Aortic Valve System  Moving to expand the evidence base for the future of structural heart disease therapy, Medtronic announced the start of the first of several new initiatives in a robust international clinical program for its CoreValve transcatheter aortic valve system.
  Medtronic, Inc. March 12, 2010  
• Monsanto welcomes chance to participate in Dept. of Justice/Dept. of Agriculture workshop  As part of today's first joint public workshop exploring competition issues in the agriculture industry, Monsanto will participate in a panel discussion about the past, present and future of the seed and trait industry.
  Monsanto Company March 12, 2010  
• FDA's Black Box Warning addressed by Genelex's PlavitestT  The FDA added a new black box warning to Plavix, pointing out the importance of individual patient genetics in determining the effectiveness of Plavix treatment. The relabeling is in response to clinical research demonstrating that one-third of patients are in varying degrees of treatment failure.
  Genelex Corporation March 12, 2010  
• Medtronic announces public offering of Senior Notes  Medtronic announced a registered offering of $1.25 billion of its 3.0 percent Senior Notes due 2015, $1.25 billion of its 4.45 percent Senior Notes due 2020 and $500 million of its 5.55 percent Senior Notes due 2040.
  Medtronic, Inc. March 11, 2010  
• Pfizer discontinues a Phase 3 study of figitumumab  Pfizer announced the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced NSCLC.
  Pfizer Inc. March 11, 2010  
• Two Phase 3 trials of sunitinib did not meet the primary endpoint  Pfizer announced that two Phase 3 studies of Sutent(R) (sunitinib malate) in advanced breast cancer did not meet their primary endpoints.
  Pfizer Inc. March 11, 2010  
• Abbott seeks FDA approval of a new six-month 45-mg formulation of Lupron(R) Depot  The U.S. Food and Drug Administration(FDA) has accepted for review the supplemental new drug application (sNDA) of a new six-month 45-mg formulation of Lupron(R) Depot (leuprolide acetate for depot suspension) for use in the palliative treatment of advanced prostate cancer.
  Abbott March 11, 2010  
• Cordis unveils next generation CoCr coronary stent  Cordis Corporation announced the European launch of its next generation of bare metal stent system - PRESILLION(TM) PLUS. The new stent system, which improves upon the ground-breaking PRESILLION(TM), features important technological advances.
  Johnson & Johnson March 11, 2010  

   (next 10 articles)